Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Access China | China Pharmaceutical Guidebook Series (4)

China Pharmaceutical Guidebook Series (4)

The biopharmaceutical industry is one of the burgeoning industries. In the field of biopharmaceuticals, vast knowledge awaits people to explore. The biopharmaceuticals are diversified and complex. In China, the development of biopharmaceutical industry is far behind the developed countries. Just for this reason, the requirements of materials and clinical trials for registration application of biopharmaceuticals stipulated by the Chinese pharmaceutical authority are far from systematic and uniform.

In China, the pharmaceutical authority ----- the SFDA (State Food and Drug Administration, China) divided the biopharmaceuticals for registration application into two classifications, i.e. the therapeutic biological products and the prophylactic biological products. However, in the classification of therapeutic biological products, the SFDA does not provide the uniform requirements of materials and clinical trials for application of biological products for the gene therapy, the somatic cell therapy and the allergic therapy, but stipulates the other guidelines for them respectively. These guidelines provide only a common principle for them because of their diversity and complexity.

This is the fourth guidebook of the China Pharmaceutical Guidebook Series. It will provide a detailed introduction of SFDA's requirements for materials and clinical trials of registration application and approval for imported biological products. This guidebook will introduce SFDA's requirements for materials and clinical trials of registration application for imported biological products in four parts and twelve chapters according to the existing a serial of regulations and guidelines. The Part I provides an introduction of the requirements for materials and clinical trials of registration application for imported therapeutic biological products. The Part II introduces the requirements for materials and clinical trials of registration application for imported prophylactic biological products. The Part III addresses the requirements for materials and clinical trials of registration application for imported gene therapeutic biological products and somatic cell therapeutic biological products. The Part IV addresses the requirements for materials and clinical trials of registration application for imported allergic therapeutic biological products.

The SFDA stipulated not only the classification of product registration but also the requirements of material items and clinical trials for various categorical biopharmaceuticals in order to administer the registration application of theirs. For every categorical biopharmaceuticals, to understand the classification of product registration only is the first step for a registration application of biological products, because applicant must file the application in accordance with the classification of biological product registration. The SFDA collected all materials submission for registration application of biological products into various items and preceded the ordinal numeral for every material item, moreover, every item includes many sub-items. When an application is filed, the SFDA will request applicant to submit the materials for registration application of biological products of various categories in accordance with the material item's ordinal numeral. Therefore, to understand the material items is the second step for registration application of biological products. The requirements of material items for registration application of biological products are introduced in terms of the form of material items and their explanatory notes. The form of material items represents the current requirements of material items for registration application of biological products stipulated by the SFDA. The explanatory notes further explain the requirements of material items for various categorical biological products. To understand the requirements for material items is a core for registration application of biological products. The application of imported biological products must accord with the material items prescribed by the form of material items and the explanatory notes to submit materials. In general, the requirements of clinical trial for registration application of biological products are two parts, i.e. the general requirements of clinical trial and the special requirements of clinical trial for imported biological products. The application of imported biological products must accord with not only the general requirements of clinical trial but also the special requirements of clinical trial for imported biological products. The application of biological products for the gene therapy, the somatic cell therapy and the allergic therapy must follow up the provisions introduced in the Chapter 10, 11, and 12 respectively.

The guidebook concludes in chapter 13 by highlighting the significant suggestions for overseas pharmaceutical manufacturers and producers looking to achieve a successful application for their biopharmaceuticals registration in China. Last, the appendices in chapter 14 include the Drug Administration Law of the People's Republic of China, the Regulations for the Drug Administration Law of the People's Republic of China, the Chinese Good Clinical Practice of Pharmaceutical Products, the Chinese Good Manufacturing Practice for Pharmaceutical Products, the Form of Registration Application for Imported Drug, references, a useful resources of URL, author's biography, and description of Access China Management Consulting Ltd. After have skimmed through this guidebook, audience can be clearly aware of the latest Chinese regulations on requirements of the materials and the clinical trials for registration application of imported biological products. For the detailed pathway and procedure for application and approval of imported biological products, audience can learn from the first guidebook of the China Pharmaceutical Guidebook Series ---- Latest Chinese Regulations for Imported Drug Registration: A Comprehensive Guidebook for Foreign Pharmaceutical Companies.

Published Date: October 2007

Page Count: 182

Unit Price: US$ 750

Site License: US$3500

Format: Electronic PDF copy

Table of Contents

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions